As weight‑loss medication becomes more widely used across the UK, expectations are growing around its potential to support chronic condition management and reduce healthcare costs. For employers, though, this is still uncharted territory. Dan Cave explores what organisations need to understand about the medication, from risk and governance to the conditions for safe, effective rollout
